MitraClip or Ventricular Assist Device?

Int Heart J. 2020 Nov 28;61(6):1303-1306. doi: 10.1536/ihj.20-333. Epub 2020 Nov 13.

Abstract

The patient was a 59-year-old female with advanced heart failure and severe functional mitral regurgitation who was classified as INTERMACS profile 4 with repeated hospitalizations despite guideline-directed medical therapy. She was also listed for heart transplantation. After comparing the two major therapeutic strategies: (1) durable left ventricular assist device (LVAD) implantation and (2) percutaneous MitraClip procedure (Abbott Vascular, Abbott Park, IL, USA), we eventually decided to proceed with MitraClip, given her relatively lower B-type natriuretic peptide, lower MAGGIC Heart Failure risk score, and higher predicted survival without LVAD. The post-procedural course was favorable without any comorbidities or worsening of heart failure for 10 months. A diagnostic paradigm to guide which strategy to choose (LVAD or MitraClip) for patients with advanced heart failure and functional mitral regurgitation should be constructed.

Keywords: Heart failure; Hemodynamics; Mitral valve disease.

Publication types

  • Case Reports

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Cardiac Resynchronization Therapy
  • Carvedilol / therapeutic use
  • Clinical Decision-Making*
  • Disease Progression
  • Enalapril / therapeutic use
  • Female
  • Heart Failure / blood
  • Heart Failure / complications
  • Heart Failure / physiopathology*
  • Heart Failure / therapy
  • Heart-Assist Devices
  • Hospitalization
  • Humans
  • Middle Aged
  • Mineralocorticoid Receptor Antagonists / therapeutic use
  • Mitral Valve Annuloplasty / methods*
  • Mitral Valve Insufficiency / complications
  • Mitral Valve Insufficiency / physiopathology
  • Mitral Valve Insufficiency / surgery*
  • Natriuretic Peptide, Brain / blood
  • Oxygen Consumption
  • Patient Selection
  • Pulmonary Wedge Pressure / physiology
  • Recurrence
  • Severity of Illness Index
  • Spironolactone / therapeutic use
  • Treatment Outcome

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Mineralocorticoid Receptor Antagonists
  • Carvedilol
  • Natriuretic Peptide, Brain
  • Spironolactone
  • Enalapril